{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:46:02Z","timestamp":1791837962896,"version":"4.3.4"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/C507237\/1"],"award-info":[{"award-number":["BB\/C507237\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["G0800498"],"award-info":[{"award-number":["G0800498"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Benzodiazepines are among the most widely prescribed psychotropic agents, exhibiting anxiolytic, hypnotic, anticonvulsant, and myorelaxant properties primarily mediated through positive allosteric modulation of type A \u03b3-aminobutyric acid receptors (GABA\n                    <jats:sub>A<\/jats:sub>\n                    Rs)\u2014the principal inhibitory receptors in the mammalian brain. However, prolonged benzodiazepine administration frequently results in the development of tolerance, a phenomenon characterized by reduced pharmacological efficacy and the need for escalating doses to sustain therapeutic benefit. Accumulating evidence indicates that benzodiazepine tolerance arises from complex neuroadaptive processes that induce long-lasting reorganization of neural circuits regulating stress responsiveness, arousal, and reward processing. In this review, we synthesize current knowledge on the clinical and societal impact of benzodiazepine use, delineate the molecular targets and mechanisms underlying their psychotropic effects on brain physiology and behaviour, and provide a comprehensive overview of the molecular and cellular adaptations contributing to benzodiazepine tolerance and withdrawal. Particular emphasis is placed on how prolonged exposure remodels inhibitory and excitatory synaptic organization. Furthermore, we examine evidence for benzodiazepine-induced synaptic adaptations in patients and highlight the potential of integrative in vivo imaging approaches to elucidate these processes within the complexity of the human brain. Finally, we propose that advancing these research avenues could foster a paradigm shift in the clinical use of benzodiazepines and guide the development of next-generation therapeutics with improved safety and efficacy profiles.\n                  <\/jats:p>","DOI":"10.1038\/s41380-026-03512-8","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:30Z","timestamp":1772119650000},"page":"3775-3785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synaptic correlates of benzodiazepine tolerance"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4019-5127","authenticated-orcid":false,"given":"Alexandre","family":"Piot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2748-743X","authenticated-orcid":false,"given":"Jasmina N.","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"3512_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2215-0366(19)30331-1","volume":"6","author":"J Marsden","year":"2019","unstructured":"Marsden J, White M, Annand F, Burkinshaw P, Carville S, Eastwood B, et al. Medicines associated with dependence or withdrawal: A mixed-methods public health review and national database study in England. Lancet Psychiatry. 2019;6:935\u201350.","journal-title":"Lancet Psychiatry"},{"key":"3512_CR2","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/bcp.14397","volume":"87","author":"J Hockenhull","year":"2021","unstructured":"Hockenhull J, Black JC, Haynes CM, Rockhill K, Dargan PI, Dart RC, Wood DM. Nonmedical use of benzodiazepines and Z-drugs in the UK. Br J Clin Pharmacol. 2021;87:1676\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"3512_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/00912174231166252","volume":"58","author":"DL Louie","year":"2023","unstructured":"Louie DL, Jegede OO, Hermes GL. Chronic use of benzodiazepines: The problem that persists. Int J Psychiatry Med. 2023;58:426\u201332.","journal-title":"Int J Psychiatry Med"},{"key":"3512_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","volume":"70","author":"S Liu","year":"2021","unstructured":"Liu S, O\u2019Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines - 38 states and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70:1136\u201341.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3512_CR5","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis. BMJ. 2017;356:j760.","journal-title":"BMJ"},{"key":"3512_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6045017","volume":"2017","author":"M Markota","year":"2017","unstructured":"Markota M, Morgan RJ. Treatment of generalized anxiety disorder with gabapentin. Case Rep Psychiatry. 2017;2017:6045017.","journal-title":"Case Rep Psychiatry"},{"key":"3512_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12630-013-9890-1","volume":"60","author":"H Clarke","year":"2013","unstructured":"Clarke H, Kirkham KR, Orser BA, Katznelson R, Mitsakakis N, Ko R, et al. Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: A blinded randomized placebo-controlled trial. Can J Anaesth. 2013;60:432\u201343.","journal-title":"Can J Anaesth"},{"key":"3512_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1526-4637.2010.00826.x","volume":"11","author":"H Clarke","year":"2010","unstructured":"Clarke H, Kay J, Orser BA, Gollish J, Mitsakakis N, Katz J. Gabapentin does not reduce preoperative anxiety when given prior to total hip arthroplasty. Pain Med. 2010;11:966\u201371.","journal-title":"Pain Med"},{"key":"3512_CR9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","volume":"27","author":"JSW Hong","year":"2022","unstructured":"Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022;27:1339\u201349.","journal-title":"Mol Psychiatry"},{"key":"3512_CR10","doi-asserted-by":"crossref","unstructured":"Eghrari NB, Yazji IH, Yavari B, Van Acker GM, Kim CH Risk of dementia following gabapentin prescription in chronic low back pain patients. Reg Anesth Pain Med. 2025:rapm-2025-106577.","DOI":"10.1136\/rapm-2025-106577"},{"key":"3512_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1128601","volume":"14","author":"YH Huang","year":"2023","unstructured":"Huang YH, Pan MH, Yang HI. The association between Gabapentin or Pregabalin use and the risk of dementia: An analysis of the National Health Insurance Research Database in Taiwan. Front Pharmacol. 2023;14:1128601.","journal-title":"Front Pharmacol"},{"key":"3512_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/papr.13400","volume":"24","author":"A Nwankwo","year":"2024","unstructured":"Nwankwo A, Koyyalagunta D, Huh B, D\u2019Souza RS, Javed S. A comprehensive review of the typical and atypical side effects of gabapentin. Pain Pract. 2024;24:1051\u20138.","journal-title":"Pain Pract"},{"key":"3512_CR13","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.3399\/bjgp17X691865","volume":"67","author":"J Davies","year":"2017","unstructured":"Davies J, Rae TC, Montagu L. Long-term benzodiazepine and Z-drugs use in England: a survey of general practice [corrected]. Br J Gen Pract. 2017;67:e609\u2013e13.","journal-title":"Br J Gen Pract"},{"key":"3512_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3399\/bjgp19X701753","volume":"69","author":"KM Kennedy","year":"2019","unstructured":"Kennedy KM, O\u2019Riordan J. Prescribing benzodiazepines in general practice. Br J Gen Pract. 2019;69:152\u20133.","journal-title":"Br J Gen Pract"},{"key":"3512_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376:1147\u201357.","journal-title":"N Engl J Med"},{"key":"3512_CR16","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.2147\/DDDT.S384155","volume":"16","author":"Q Hu","year":"2022","unstructured":"Hu Q, Liu X, Wen C, Li D, Lei X. Remimazolam: An Updated Review of a New Sedative and Anaesthetic. Drug Des Devel Ther. 2022;16:3957\u201374.","journal-title":"Drug Des Devel Ther"},{"key":"3512_CR17","doi-asserted-by":"publisher","first-page":"231S","DOI":"10.1111\/j.1365-2125.1983.tb02295.x","volume":"16","author":"P Danneberg","year":"1983","unstructured":"Danneberg P, Weber K. Chemical structure and biological activity of the diazepines. Br J Clin Pharmacol. 1983;16:231S\u201344S.","journal-title":"Br J Clin Pharmacol"},{"key":"3512_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/clpt.1992.123","volume":"52","author":"H Friedman","year":"1992","unstructured":"Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther. 1992;52:139\u201350.","journal-title":"Clin Pharmacol Ther"},{"key":"3512_CR19","first-page":"214","volume":"13","author":"CE Griffin","year":"2013","unstructured":"Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system\u2013mediated effects. Ochsner J. 2013;13:214\u201323.","journal-title":"Ochsner J"},{"key":"3512_CR20","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/0002-9343(90)90281-H","volume":"88","author":"DJ Greenblatt","year":"1990","unstructured":"Greenblatt DJ, Miller LG, Shader RI. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med. 1990;88:S18\u2013S24.","journal-title":"Am J Med"},{"key":"3512_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1381612023396681","volume":"8","author":"A Bateson","year":"2002","unstructured":"Bateson A. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des. 2002;8:5\u201321.","journal-title":"Curr Pharm Des"},{"key":"3512_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.phrs.2015.12.030","volume":"109","author":"MC Gravielle","year":"2016","unstructured":"Gravielle MC. Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance? Pharmacol Res. 2016;109:92\u2013100.","journal-title":"Pharmacol Res"},{"key":"3512_CR23","first-page":"121","volume":"26","author":"A Kales","year":"1983","unstructured":"Kales A, Soldatos CR, Bixler EO, Kales JD. Rebound insomnia and rebound anxiety: A review. Pharmacology. 1983;26:121\u201337.","journal-title":"Pharmacology"},{"key":"3512_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00004850-199909000-00004","volume":"14","author":"CR Soldatos","year":"1999","unstructured":"Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: A meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14:287\u2013303.","journal-title":"Int Clin Psychopharmacol"},{"key":"3512_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100270","volume":"12","author":"CF Sun","year":"2024","unstructured":"Sun CF, Pola AS, Su KP, Lin BY, Kablinger AS, Trestman RL. Benzodiazepine use for anxiety disorders is associated with increased long-term risk of mood and substance use disorders: A large-scale retrospective cohort study. Drug Alcohol Depend Rep. 2024;12:100270.","journal-title":"Drug Alcohol Depend Rep"},{"key":"3512_CR26","doi-asserted-by":"publisher","first-page":"e44797","DOI":"10.1097\/MD.0000000000044797","volume":"104","author":"W Guo","year":"2025","unstructured":"Guo W, Zhang C, Yang R, Yan L. What does data on adverse reactions reveal about benzodiazepines and suicide-related risk?: A disproportionality analysis using FDA FAERS pharmacovigilance data. Medicine (Baltimore). 2025;104:e44797.","journal-title":"Medicine (Baltimore)"},{"key":"3512_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1060949","volume":"13","author":"E Engin","year":"2022","unstructured":"Engin E. GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse. Front Psychiatry. 2022;13:1060949.","journal-title":"Front Psychiatry"},{"key":"3512_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0006-8993(96)00644-0","volume":"734","author":"C Fernandes","year":"1996","unstructured":"Fernandes C, File SE, Berry D. Evidence against oppositional and pharmacokinetic mechanisms of tolerance to diazepam\u2019s sedative effects. Brain Res. 1996;734:236\u201342.","journal-title":"Brain Res"},{"key":"3512_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H Petursson","year":"1994","unstructured":"Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89:1455\u20139.","journal-title":"Addiction"},{"key":"3512_CR30","first-page":"416864","volume":"2012","author":"CH Vinkers","year":"2012","unstructured":"Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. 2012;2012:416864.","journal-title":"Adv Pharmacol Sci"},{"key":"3512_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0269881120981390","volume":"35","author":"AT Gallo","year":"2021","unstructured":"Gallo AT, Hulse G. Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021;35:211\u201320.","journal-title":"J Psychopharmacol"},{"key":"3512_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.646038","volume":"12","author":"A Benini","year":"2021","unstructured":"Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous infusion of flumazenil in the management of benzodiazepines detoxification. Front Psychiatry. 2021;12:646038.","journal-title":"Front Psychiatry"},{"key":"3512_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yebeh.2011.11.005","volume":"23","author":"A Albiero","year":"2012","unstructured":"Albiero A, Brigo F, Faccini M, Casari R, Quaglio G, Storti M, et al. Focal nonconvulsive seizures during detoxification for benzodiazepine abuse. Epilepsy Behav. 2012;23:168\u201370.","journal-title":"Epilepsy Behav"},{"key":"3512_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.12023","volume":"77","author":"SD Hood","year":"2014","unstructured":"Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77:285\u201394.","journal-title":"Br J Clin Pharmacol"},{"key":"3512_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2024.173895","volume":"245","author":"R Cerne","year":"2024","unstructured":"Cerne R, Smith JL, Chrzanowska A, Lippa A. Nonsedating anxiolytics. Pharmacol Biochem Behav. 2024;245:173895.","journal-title":"Pharmacol Biochem Behav"},{"key":"3512_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41386-023-01728-8","volume":"49","author":"SM Thompson","year":"2024","unstructured":"Thompson SM. Modulators of GABA(A) receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future. Neuropsychopharmacology. 2024;49:83\u201395.","journal-title":"Neuropsychopharmacology"},{"key":"3512_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.616298","volume":"14","author":"D Castellano","year":"2020","unstructured":"Castellano D, Shepard RD, Lu W. Looking for Novelty in an \u201cOld\u201d Receptor: Recent Advances Toward Our Understanding of GABA(A)Rs and Their Implications in Receptor Pharmacology. Front Neurosci. 2020;14:616298.","journal-title":"Front Neurosci"},{"key":"3512_CR38","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1021\/acs.jmedchem.9b01312","volume":"63","author":"S Maramai","year":"2020","unstructured":"Maramai S, Benchekroun M, Ward SE, Atack JR. Subtype Selective gamma-Aminobutyric Acid Type A Receptor (GABA(A)R) modulators acting at the benzodiazepine binding site: An update. J Med Chem. 2020;63:3425\u201346.","journal-title":"J Med Chem"},{"key":"3512_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.sbi.2019.03.023","volume":"54","author":"S Scott","year":"2019","unstructured":"Scott S, Aricescu AR. A structural perspective on GABA(A) receptor pharmacology. Curr Opin Struct Biol. 2019;54:189\u201397.","journal-title":"Curr Opin Struct Biol"},{"key":"3512_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11011-014-9560-1","volume":"30","author":"C Wu","year":"2015","unstructured":"Wu C, Sun D. GABA receptors in brain development, function, and injury. Metab Brain Dis. 2015;30:367\u201379.","journal-title":"Metab Brain Dis"},{"key":"3512_CR41","first-page":"65","volume-title":"U: GABA And Glutamate-New Developments In Neurotransmission Research Samardzic J, ur","author":"CS Hampe","year":"2018","unstructured":"Hampe CS, Mitoma H, Manto M. GABA and Glutamate: Their transmitter role in the CNS and pancreatic islets. U: GABA And Glutamate-New Developments In Neurotransmission Research Samardzic J, ur. London: IntechOpen; 2018. p. 65\u201390."},{"key":"3512_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.conb.2013.11.004","volume":"26","author":"K Kaila","year":"2014","unstructured":"Kaila K, Ruusuvuori E, Seja P, Voipio J, Puskarjov M. GABA actions and ionic plasticity in epilepsy. Curr Opin Neurobiol. 2014;26:34\u201341.","journal-title":"Curr Opin Neurobiol"},{"key":"3512_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neubiorev.2015.12.014","volume":"62","author":"AK Shetty","year":"2016","unstructured":"Shetty AK, Upadhya D. GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges. Neurosci Biobehav Rev. 2016;62:35\u201347.","journal-title":"Neurosci Biobehav Rev"},{"key":"3512_CR44","first-page":"165","volume":"11","author":"P Nuss","year":"2015","unstructured":"Nuss P. Anxiety disorders and GABA neurotransmission: A disturbance of modulation. Neuropsychiatr Dis Treat. 2015;11:165.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3512_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fncel.2019.00087","volume":"13","author":"MV Fogaca","year":"2019","unstructured":"Fogaca MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: New insights for therapeutic interventions. Front Cell Neurosci. 2019;13:87.","journal-title":"Front Cell Neurosci"},{"key":"3512_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/npp.2014.95","volume":"40","author":"MJ Schmidt","year":"2015","unstructured":"Schmidt MJ, Mirnics K. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology. 2015;40:190\u2013206.","journal-title":"Neuropsychopharmacology"},{"key":"3512_CR47","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1007\/s00018-021-03846-2","volume":"78","author":"E Sallard","year":"2021","unstructured":"Sallard E, Letourneur D, Legendre P. Electrophysiology of ionotropic GABA receptors. Cell Mol Life Sci. 2021;78:5341\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"3512_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/2398212819858249","volume":"3","author":"TG Smart","year":"2019","unstructured":"Smart TG, Stephenson FA. A half century of gamma-aminobutyric acid. Brain Neurosci Adv. 2019;3:2398212819858249.","journal-title":"Brain Neurosci Adv"},{"key":"3512_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apha.2017.03.003","volume":"79","author":"HC Chua","year":"2017","unstructured":"Chua HC, Chebib M. GABA(A) receptors and the diversity in their structure and pharmacology. Adv Pharmacol. 2017;79:1\u201334.","journal-title":"Adv Pharmacol"},{"key":"3512_CR50","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1523\/JNEUROSCI.5663-11.2012","volume":"32","author":"MC Gielen","year":"2012","unstructured":"Gielen MC, Lumb MJ, Smart TG. Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding. J Neurosci. 2012;32:5707\u201315.","journal-title":"J Neurosci"},{"key":"3512_CR51","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","volume":"565","author":"S Masiulis","year":"2019","unstructured":"Masiulis S, Desai R, Uchanski T, Serna Martin I, Laverty D, Karia D, et al. GABA(A) receptor signalling mechanisms revealed by structural pharmacology. Nature. 2019;565:454\u20139.","journal-title":"Nature"},{"key":"3512_CR52","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1476-5381.2011.01779.x","volume":"166","author":"W Sieghart","year":"2012","unstructured":"Sieghart W, Ramerstorfer J, Sarto\u2010Jackson I, Varagic Z, Ernst M. A novel GABAA receptor pharmacology: Drugs interacting with the \u03b1+ \u03b2\u2010interface. Br J Pharmacol. 2012;166:476\u201385.","journal-title":"Br J Pharmacol"},{"key":"3512_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1113\/jphysiol.1991.sp018512","volume":"435","author":"RE Twyman","year":"1991","unstructured":"Twyman RE, Macdonald RL. Kinetic properties of the glycine receptor main- and sub-conductance states of mouse spinal cord neurones in culture. J Physiol. 1991;435:303\u201331.","journal-title":"J Physiol"},{"key":"3512_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1124\/mol.104.002543","volume":"66","author":"HJ Feng","year":"2004","unstructured":"Feng HJ, Bianchi MT, Macdonald RL. Pentobarbital differentially modulates alpha1beta3delta and alpha1beta3gamma2L GABAA receptor currents. Mol Pharmacol. 2004;66:988\u20131003.","journal-title":"Mol Pharmacol"},{"key":"3512_CR55","doi-asserted-by":"publisher","first-page":"17971","DOI":"10.1021\/acs.jmedchem.5c01770","volume":"68","author":"Y Gao","year":"2025","unstructured":"Gao Y, Noraddin A, Li X, Zhu C, Zhang Y, Jin Y, et al. Discovery of novel antiepileptic agents targeting the alpha1beta2gamma2 GABA(A) receptor. J Med Chem. 2025;68:17971\u201389.","journal-title":"J Med Chem"},{"key":"3512_CR56","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1021\/acschembio.8b00144","volume":"13","author":"AA Elgarf","year":"2018","unstructured":"Elgarf AA, Siebert DC, Steudle F, Draxler A, Li G, Huang S, et al. Different benzodiazepines bind with distinct binding modes to GABAA Receptors. ACS Chem Biol. 2018;13:2033\u20139.","journal-title":"ACS Chem Biol"},{"key":"3512_CR57","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","volume":"34","author":"KR Tan","year":"2011","unstructured":"Tan KR, Rudolph U, L\u00fcscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34:188\u201397.","journal-title":"Trends Neurosci"},{"key":"3512_CR58","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolf","year":"1999","unstructured":"Rudolf U, Crestani F, Benke J, Br\u00fcnig I, Benson J, Fritschy J, et al. Benzodiazepine actions mediated by specific m-aminobutyric acidA receptor suptypes. Nature. 1999;401:796\u2013800.","journal-title":"Nature"},{"key":"3512_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1126\/science.290.5489.131","volume":"290","author":"K Low","year":"2000","unstructured":"Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131\u20134.","journal-title":"Science"},{"key":"3512_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0026-895X(24)12233-X","volume":"59","author":"F Crestani","year":"2001","unstructured":"Crestani F, L\u00f6w K, Keist R, Mandelli M-J, M\u00f6hler H, Rudolph U. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 2001;59:442\u20135.","journal-title":"Mol Pharmacol"},{"key":"3512_CR61","doi-asserted-by":"publisher","first-page":"8980","DOI":"10.1073\/pnas.142288699","volume":"99","author":"F Crestani","year":"2002","unstructured":"Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci USA. 2002;99:8980\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3512_CR62","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1523\/JNEUROSCI.5024-05.2006","volume":"26","author":"VY Cheng","year":"2006","unstructured":"Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HT, Taverna FA, et al. \u03b15GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci. 2006;26:3713\u201320.","journal-title":"J Neurosci"},{"key":"3512_CR63","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00018-012-0926-4","volume":"69","author":"JM Fritschy","year":"2012","unstructured":"Fritschy JM, Panzanelli P, Tyagarajan SK. Molecular and functional heterogeneity of GABAergic synapses. Cell Mol Life Sci. 2012;69:2485\u201399.","journal-title":"Cell Mol Life Sci"},{"key":"3512_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrn1625","volume":"6","author":"M Farrant","year":"2005","unstructured":"Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005;6:215\u201329.","journal-title":"Nat Rev Neurosci"},{"key":"3512_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2022.914374","volume":"14","author":"AE Tipton","year":"2022","unstructured":"Tipton AE, Russek SJ. Regulation of inhibitory signaling at the receptor and cellular level; Advances in our understanding of GABAergic neurotransmission and the mechanisms by which it is disrupted in epilepsy. Front Synaptic Neurosci. 2022;14:914374.","journal-title":"Front Synaptic Neurosci"},{"key":"3512_CR66","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tins.2020.10.011","volume":"44","author":"W Han","year":"2021","unstructured":"Han W, Shepard RD, Lu W. Regulation of GABA(A)Rs by transmembrane accessory proteins. Trends Neurosci. 2021;44:152\u201365.","journal-title":"Trends Neurosci"},{"key":"3512_CR67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroscience.2019.07.036","volume":"439","author":"R Pizzarelli","year":"2020","unstructured":"Pizzarelli R, Griguoli M, Zacchi P, Petrini EM, Barberis A, Cattaneo A, Cherubini E. Tuning GABAergic inhibition: Gephyrin molecular organization and functions. Neuroscience. 2020;439:125\u201336.","journal-title":"Neuroscience"},{"key":"3512_CR68","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.conb.2024.102952","volume":"90","author":"TM Welle","year":"2024","unstructured":"Welle TM, Smith KR. Release your inhibitions: The cell biology of GABAergic postsynaptic plasticity. Curr Opin Neurobiol. 2024;90:102952.","journal-title":"Curr Opin Neurobiol"},{"key":"3512_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tins.2024.11.007","volume":"48","author":"D Krueger-Burg","year":"2025","unstructured":"Krueger-Burg D. Understanding GABAergic synapse diversity and its implications for GABAergic pharmacotherapy. Trends Neurosci. 2025;48:47\u201361.","journal-title":"Trends Neurosci"},{"key":"3512_CR70","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1073\/pnas.74.9.3805","volume":"74","author":"C Braestrup","year":"1977","unstructured":"Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA. 1977;74:3805\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3512_CR71","doi-asserted-by":"publisher","first-page":"16788","DOI":"10.1523\/JNEUROSCI.4101-10.2010","volume":"30","author":"K Tokuda","year":"2010","unstructured":"Tokuda K, O\u2019Dell KA, Izumi Y, Zorumski CF. Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. J Neurosci. 2010;30:16788\u201395.","journal-title":"J Neurosci"},{"key":"3512_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.apha.2017.09.004","volume":"82","author":"M Gavish","year":"2018","unstructured":"Gavish M, Veenman L. Regulation of mitochondrial, cellular, and organismal functions by TSPO. Adv Pharmacol. 2018;82:103\u201336.","journal-title":"Adv Pharmacol"},{"key":"3512_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/978-3-031-55529-9_32","volume":"37","author":"J Ottoy","year":"2024","unstructured":"Ottoy J, De Picker L, Kang MS. Microglial positron emission tomography imaging in vivo: Positron emission tomography radioligands: Utility in research and clinical practice. Adv Neurobiol. 2024;37:579\u201389.","journal-title":"Adv Neurobiol."},{"key":"3512_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/ijms18040785","volume":"18","author":"AC Dupont","year":"2017","unstructured":"Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18:785.","journal-title":"Int J Mol Sci"},{"key":"3512_CR75","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.expneurol.2009.04.016","volume":"219","author":"V Papadopoulos","year":"2009","unstructured":"Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol. 2009;219:53\u20137.","journal-title":"Exp Neurol"},{"key":"3512_CR76","first-page":"483","volume":"12","author":"B Costa","year":"2012","unstructured":"Costa B, Pini S, Abelli M, Gabelloni P, Da Pozzo E, Chelli B, et al. Role of translocator protein (18 kDa) in adult separation anxiety and attachment style in patients with depression. Curr Mol Med. 2012;12:483\u20137.","journal-title":"Curr Mol Med"},{"key":"3512_CR77","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12035-020-02136-5","volume":"58","author":"AM Barron","year":"2021","unstructured":"Barron AM, Higuchi M, Hattori S, Kito S, Suhara T, Ji B. Regulation of anxiety and depression by mitochondrial translocator protein-mediated steroidogenesis: The role of neurons. Mol Neurobiol. 2021;58:550\u201363.","journal-title":"Mol Neurobiol"},{"key":"3512_CR78","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.1175055","volume":"325","author":"R Rupprecht","year":"2009","unstructured":"Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325:490\u20133.","journal-title":"Science"},{"key":"3512_CR79","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41380-022-01561-3","volume":"27","author":"R Rupprecht","year":"2022","unstructured":"Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, et al. Translocator protein (18kDa) TSPO: A new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry. 2022;27:2918\u201326.","journal-title":"Mol Psychiatry"},{"key":"3512_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1210205","volume":"17","author":"G Cheung","year":"2023","unstructured":"Cheung G, Lin YC, Papadopoulos V. Translocator protein in the rise and fall of central nervous system neurons. Front Cell Neurosci. 2023;17:1210205.","journal-title":"Front Cell Neurosci"},{"key":"3512_CR81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41593-022-01013-9","volume":"25","author":"Y Shi","year":"2022","unstructured":"Shi Y, Cui M, Ochs K, Brendel M, Strubing FL, Briel N, et al. Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO). Nat Neurosci. 2022;25:317\u201329.","journal-title":"Nat Neurosci"},{"key":"3512_CR82","first-page":"395","volume":"19","author":"DS Reddy","year":"1997","unstructured":"Reddy DS, Kulkarni SK. Neurosteroid coadministration prevents development of tolerance and augments recovery from benzodiazepine withdrawal anxiety and hyperactivity in mice. Methods Find Exp Clin Pharmacol. 1997;19:395\u2013405.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"3512_CR83","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0014-2999(89)90535-9","volume":"170","author":"TD Hernandez","year":"1989","unstructured":"Hernandez TD, Heninger C, Wilson MA, Gallager DW. Relationship of agonist efficacy to changes in GABA sensitivity and anticonvulsant tolerance following chronic benzodiazepine ligand exposure. Eur J Pharmacol. 1989;170:145\u201355.","journal-title":"Eur J Pharmacol"},{"key":"3512_CR84","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1046\/j.1471-4159.1994.63062349.x","volume":"63","author":"RL Klein","year":"1994","unstructured":"Klein RL, Whiting PJ, Harris RA. Benzodiazepine treatment causes uncoupling of recombinant GABAA receptors expressed in stably transfected cells. J Neurochem. 1994;63:2349\u201352.","journal-title":"J Neurochem"},{"key":"3512_CR85","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1046\/j.1471-4159.1999.0722219.x","volume":"72","author":"RA Holt","year":"1999","unstructured":"Holt RA, Bateson AN, Martin IL. Decreased GABA enhancement of benzodiazepine binding after a single dose of diazepam. J Neurochem. 1999;72:2219\u201322.","journal-title":"J Neurochem"},{"key":"3512_CR86","doi-asserted-by":"publisher","first-page":"20954","DOI":"10.1074\/jbc.M500131200","volume":"280","author":"MC Gravielle","year":"2005","unstructured":"Gravielle MC, Faris R, Russek SJ, Farb DH. GABA induces activity dependent delayed-onset uncoupling of GABA\/benzodiazepine site interactions in neocortical neurons. J Biol Chem. 2005;280:20954\u201360.","journal-title":"J Biol Chem"},{"key":"3512_CR87","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jnr.23387","volume":"92","author":"ML Gutierrez","year":"2014","unstructured":"Gutierrez ML, Ferreri MC, Farb DH, Gravielle MC. GABA-induced uncoupling of GABA\/benzodiazepine site interactions is associated with increased phosphorylation of the GABAA receptor. J Neurosci Res. 2014;92:1054\u201361.","journal-title":"J Neurosci Res"},{"key":"3512_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22420-9","volume":"12","author":"M Field","year":"2021","unstructured":"Field M, Dorovykh V, Thomas P, Smart TG. Physiological role for GABA(A) receptor desensitization in the induction of long-term potentiation at inhibitory synapses. Nat Commun. 2021;12:2112.","journal-title":"Nat Commun"},{"key":"3512_CR89","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.aax5719","volume":"366","author":"W Han","year":"2019","unstructured":"Han W, Li J, Pelkey KA, Pandey S, Chen X, Wang YX, et al. Shisa7 is a GABA(A) receptor auxiliary subunit controlling benzodiazepine actions. Science. 2019;366:246\u201350.","journal-title":"Science"},{"key":"3512_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.022","volume":"169","author":"S Hannan","year":"2020","unstructured":"Hannan S, Minere M, Harris J, Izquierdo P, Thomas P, Tench B, Smart TG. GABA(A)R isoform and subunit structural motifs determine synaptic and extrasynaptic receptor localisation. Neuropharmacology. 2020;169:107540.","journal-title":"Neuropharmacology"},{"key":"3512_CR91","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mcn.2014.10.004","volume":"63","author":"G Gouzer","year":"2014","unstructured":"Gouzer G, Specht CG, Allain L, Shinoe T, Triller A. Benzodiazepine-dependent stabilization of GABA(A) receptors at synapses. Mol Cell Neurosci. 2014;63:101\u201313.","journal-title":"Mol Cell Neurosci"},{"key":"3512_CR92","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuropharm.2014.06.002","volume":"88","author":"S Levi","year":"2015","unstructured":"Levi S, Le Roux N, Eugene E, Poncer JC. Benzodiazepine ligands rapidly influence GABAA receptor diffusion and clustering at hippocampal inhibitory synapses. Neuropharmacology. 2015;88:199\u2013208.","journal-title":"Neuropharmacology"},{"key":"3512_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7872","volume":"6","author":"TJ Hausrat","year":"2015","unstructured":"Hausrat TJ, Muhia M, Gerrow K, Thomas P, Hirdes W, Tsukita S, et al. Radixin regulates synaptic GABAA receptor density and is essential for reversal learning and short-term memory. Nat Commun. 2015;6:6872.","journal-title":"Nat Commun"},{"key":"3512_CR94","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-3565(25)12410-5","volume":"276","author":"RJ Primus","year":"1996","unstructured":"Primus RJ, Yu J, Xu J, Hartnett C, Meyyappan M, Kostas C, et al. Allosteric uncoupling after chronic benzodiazepine exposure of recombinant gamma-aminobutyric acid(A) receptors expressed in Sf9 cells: ligand efficacy and subtype selectivity. J Pharmacol Exp Ther. 1996;276:882\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"3512_CR95","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/308074a0","volume":"308","author":"DW Gallager","year":"1984","unstructured":"Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature. 1984;308:74\u20137.","journal-title":"Nature"},{"key":"3512_CR96","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1152\/physrev.00015.2010","volume":"91","author":"M Vithlani","year":"2011","unstructured":"Vithlani M, Terunuma M, Moss SJ. The dynamic modulation of GABA(A) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. Physiol Rev. 2011;91:1009\u201322.","journal-title":"Physiol Rev"},{"key":"3512_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fncel.2019.00163","volume":"13","author":"JM Lorenz-Guertin","year":"2019","unstructured":"Lorenz-Guertin JM, Bambino MJ, Das S, Weintraub ST, Jacob TC. Diazepam accelerates GABA(A)R synaptic exchange and alters intracellular trafficking. Front Cell Neurosci. 2019;13:163.","journal-title":"Front Cell Neurosci"},{"key":"3512_CR98","doi-asserted-by":"publisher","first-page":"18595","DOI":"10.1073\/pnas.1204994109","volume":"109","author":"TC Jacob","year":"2012","unstructured":"Jacob TC, Michels G, Silayeva L, Haydon J, Succol F, Moss SJ. Benzodiazepine treatment induces subtype-specific changes in GABAA receptor trafficking and decreases synaptic inhibition. Proc Natl Acad Sci. 2012;109:18595\u2013600.","journal-title":"Proc Natl Acad Sci"},{"key":"3512_CR99","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41380-018-0100-y","volume":"23","author":"MW Nicholson","year":"2018","unstructured":"Nicholson MW, Sweeney A, Pekle E, Alam S, Ali AB, Duchen M, Jovanovic JN. Diazepam-induced loss of inhibitory synapses mediated by PLC\u03b4\/Ca 2+\/calcineurin signalling downstream of GABAA receptors. Mol Psychiatry. 2018;23:1851\u201367.","journal-title":"Mol Psychiatry"},{"key":"3512_CR100","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neuron.2009.12.007","volume":"65","author":"AE Twelvetrees","year":"2010","unstructured":"Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, MacAskill AF, Rostaing P, Lumb MJ, et al. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron. 2010;65:53\u201365.","journal-title":"Neuron"},{"key":"3512_CR101","doi-asserted-by":"publisher","first-page":"17552","DOI":"10.1073\/pnas.0905502106","volume":"106","author":"IL Arancibia-Carcamo","year":"2009","unstructured":"Arancibia-Carcamo IL, Yuen EY, Muir J, Lumb MJ, Michels G, Saliba RS, et al. Ubiquitin-dependent lysosomal targeting of GABA(A) receptors regulates neuronal inhibition. Proc Natl Acad Sci USA. 2009;106:17552\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3512_CR102","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0022-3565(24)37019-3","volume":"283","author":"MH Tehrani","year":"1997","unstructured":"Tehrani MH, Barnes EM Jr. Sequestration of gamma-aminobutyric acidA receptors on clathrin-coated vesicles during chronic benzodiazepine administration in vivo. J Pharmacol Exp Ther. 1997;283:384\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"3512_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2015.12.048","volume":"613","author":"Y Curto","year":"2016","unstructured":"Curto Y, Garcia-Mompo C, Bueno-Fernandez C, Nacher J. Chronic benzodiazepine treatment decreases spine density in cortical pyramidal neurons. Neurosci Lett. 2016;613:41\u20136.","journal-title":"Neurosci Lett"},{"key":"3512_CR104","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1124\/pr.109.002063","volume":"62","author":"M Uusi-Oukari","year":"2010","unstructured":"Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev. 2010;62:97\u2013135.","journal-title":"Pharmacol Rev"},{"key":"3512_CR105","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02876917","volume":"2","author":"C Heninger","year":"1990","unstructured":"Heninger C, Saito N, Tallman JF, Garrett KM, Vitek MP, Duman RS, Gallager DW. Effects of continuous diazepam administration on GABAA subunit mRNA in rat brain. J Mol Neurosci. 1990;2:101\u20137.","journal-title":"J Mol Neurosci"},{"key":"3512_CR106","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1476-5381.1991.tb09781.x","volume":"103","author":"I Kang","year":"1991","unstructured":"Kang I, Miller LG. Decreased GABAA receptor subunit mRNA concentrations following chronic lorazepam administration. Br J Pharmacol. 1991;103:1285\u20137.","journal-title":"Br J Pharmacol"},{"key":"3512_CR107","doi-asserted-by":"publisher","first-page":"134801","DOI":"10.1016\/j.neulet.2020.134801","volume":"721","author":"MF Foitzick","year":"2020","unstructured":"Foitzick MF, Medina NB, Iglesias Garcia LC, Gravielle MC. Benzodiazepine exposure induces transcriptional down-regulation of GABA(A) receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons. Neurosci Lett. 2020;721:134801.","journal-title":"Neurosci Lett"},{"key":"3512_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0922-4106(92)90078-A","volume":"226","author":"RJ Primus","year":"1992","unstructured":"Primus RJ, Gallager DW. GABAA receptor subunit mRNA levels are differentially influenced by chronic FG 7142 and diazepam exposure. Eur J Pharmacol. 1992;226:21\u20138.","journal-title":"Eur J Pharmacol"},{"key":"3512_CR109","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02736752","volume":"5","author":"Y Wu","year":"1994","unstructured":"Wu Y, Rosenberg HC, Chiu TH, Zhao TJ. Subunit- and brain region-specific reduction of GABAA receptor subunit mRNAs during chronic treatment of rats with diazepam. J Mol Neurosci. 1994;5:105\u201320.","journal-title":"J Mol Neurosci"},{"key":"3512_CR110","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0169-328X(97)00129-0","volume":"48","author":"RA Holt","year":"1997","unstructured":"Holt RA, Martin IL, Bateson AN. Chronic diazepam exposure decreases transcription of the rat GABA(A) receptor gamma2-subunit gene. Brain Res Mol Brain Res. 1997;48:164\u20136.","journal-title":"Brain Res Mol Brain Res"},{"key":"3512_CR111","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0306-4522(98)00516-8","volume":"91","author":"EI Tietz","year":"1999","unstructured":"Tietz EI, Huang X, Chen S, Ferencak WF 3rd. Temporal and regional regulation of alpha1, beta2 and beta3, but not alpha2, alpha4, alpha5, alpha6, beta1 or gamma2 GABA(A) receptor subunit messenger RNAs following one-week oral flurazepam administration. Neuroscience. 1999;91:327\u201341.","journal-title":"Neuroscience"},{"key":"3512_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.416","volume":"6","author":"J Auta","year":"2018","unstructured":"Auta J, Gatta E, Davis JM, Pandey SC, Guidotti A. Potential role for histone deacetylation in chronic diazepam-induced downregulation of alpha1-GABA(A) receptor subunit expression. Pharmacol Res Perspect. 2018;6:e00416.","journal-title":"Pharmacol Res Perspect"},{"key":"3512_CR113","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0028-3908(96)00064-0","volume":"35","author":"RA Holt","year":"1996","unstructured":"Holt RA, Bateson AN, Martin IL. Chronic treatment with diazepam or abecarnil differently affects the expression of GABAA receptor subunit mRNAs in the rat cortex. Neuropharmacology. 1996;35:1457\u201363.","journal-title":"Neuropharmacology"},{"key":"3512_CR114","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.euroneuro.2014.11.004","volume":"25","author":"GM Leggio","year":"2015","unstructured":"Leggio GM, Torrisi SA, Castorina A, Platania CB, Impellizzeri AA, Fidilio A, et al. Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. Eur Neuropsychopharmacol. 2015;25:1427\u201336.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3512_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106248","volume":"185","author":"JM Lorenz-Guertin","year":"2023","unstructured":"Lorenz-Guertin JM, Povysheva N, Chapman CA, MacDonald ML, Fazzari M, Nigam A, et al. Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiol Dis. 2023;185:106248.","journal-title":"Neurobiol Dis"},{"key":"3512_CR116","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1523\/JNEUROSCI.1067-04.2004","volume":"24","author":"C van Rijnsoever","year":"2004","unstructured":"van Rijnsoever C, Tauber M, Choulli MK, Keist R, Rudolph U, Mohler H, et al. Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci. 2004;24:6785\u201390.","journal-title":"J Neurosci"},{"key":"3512_CR117","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/030006059202000208","volume":"20","author":"L Maarek","year":"1992","unstructured":"Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice. J Int Med Res. 1992;20:162\u201370.","journal-title":"J Int Med Res"},{"key":"3512_CR118","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1093\/ajhp\/53.21.2638","volume":"53","author":"LGB Sanchez","year":"1996","unstructured":"Sanchez LGB, Sanchez JM, Moreno JLL. Dependence and tolerance with Zolpidem. Am J Health Syst Pharm. 1996;53:2638.","journal-title":"Am J Health Syst Pharm"},{"key":"3512_CR119","doi-asserted-by":"publisher","first-page":"7972","DOI":"10.1523\/JNEUROSCI.20-21-07972.2000","volume":"20","author":"JT Kittler","year":"2000","unstructured":"Kittler JT, Delmas P, Jovanovic JN, Brown DA, Smart TG, Moss SJ. Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J Neurosci. 2000;20:7972\u20137.","journal-title":"J Neurosci"},{"key":"3512_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevImmunol.2025057969","volume":"45","author":"VD Nimbarte","year":"2025","unstructured":"Nimbarte VD, Sonak SS, Ishwarkar S. Understanding the impact of calcineurin inhibitors on T cell regulation: Mechanisms and clinical implications. Crit Rev Immunol. 2025;45:43\u201356.","journal-title":"Crit Rev Immunol"},{"key":"3512_CR121","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jbior.2013.07.001","volume":"53","author":"G Sugiyama","year":"2013","unstructured":"Sugiyama G, Takeuchi H, Kanematsu T, Gao J, Matsuda M, Hirata M. Phospholipase C-related but catalytically inactive protein, PRIP as a scaffolding protein for phospho-regulation. Adv Biol Regul. 2013;53:331\u201340.","journal-title":"Adv Biol Regul"},{"key":"3512_CR122","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00424-014-1592-1","volume":"467","author":"H Toyoda","year":"2015","unstructured":"Toyoda H, Saito M, Sato H, Kawano T, Kawakami S, Yatani H, et al. Enhanced lateral inhibition in the barrel cortex by deletion of phospholipase C-related catalytically inactive protein-1\/2 in mice. Pflugers Arch. 2015;467:1445\u201356.","journal-title":"Pflugers Arch"},{"key":"3512_CR123","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/emboj\/21.5.1004","volume":"21","author":"T Kanematsu","year":"2002","unstructured":"Kanematsu T, Jang IS, Yamaguchi T, Nagahama H, Yoshimura K, Hidaka K, et al. Role of the PLC-related, catalytically inactive protein p130 in GABA(A) receptor function. EMBO J. 2002;21:1004\u201311.","journal-title":"EMBO J"},{"key":"3512_CR124","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0163-7258(03)00029-9","volume":"98","author":"C Allison","year":"2003","unstructured":"Allison C, Pratt J. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003;98:171\u201395.","journal-title":"Pharmacol Ther"},{"key":"3512_CR125","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0022-3565(25)20998-3","volume":"246","author":"LG Miller","year":"1988","unstructured":"Miller LG, Greenblatt DJ, Barnhill JG, Shader RI. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function. J Pharmacol Exp Ther. 1988;246:170\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"3512_CR126","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-3-031-36159-3_6","volume":"34","author":"AA Rasia-Filho","year":"2023","unstructured":"Rasia-Filho AA, Calcagnotto ME, von Bohlen Und Halbach O. Glial cell modulation of dendritic spine structure and synaptic function. Adv Neurobiol. 2023;34:255\u2013310.","journal-title":"Adv Neurobiol"},{"key":"3512_CR127","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37\u201348.","journal-title":"CNS Drugs"},{"key":"3512_CR128","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pbb.2008.12.015","volume":"92","author":"T Aitta-Aho","year":"2009","unstructured":"Aitta-Aho T, Vekovischeva OY, Neuvonen PJ, Korpi ER. Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. Pharmacol Biochem Behav. 2009;92:283\u201390.","journal-title":"Pharmacol Biochem Behav"},{"key":"3512_CR129","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/S0014-2999(97)01501-X","volume":"341","author":"M Tsuda","year":"1998","unstructured":"Tsuda M, Chiba Y, Suzuki T, Misawa M. Upregulation of NMDA receptor subunit proteins in the cerebral cortex during diazepam withdrawal. Eur J Pharmacol. 1998;341:R1\u2013R2.","journal-title":"Eur J Pharmacol"},{"key":"3512_CR130","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41582-022-00664-3","volume":"18","author":"RJ Burman","year":"2022","unstructured":"Burman RJ, Rosch RE, Wilmshurst JM, Sen A, Ramantani G, Akerman CJ, Raimondo JV. Why won\u2019t it stop? The dynamics of benzodiazepine resistance in status epilepticus. Nat Rev Neurol. 2022;18:428\u201341.","journal-title":"Nat Rev Neurol"},{"key":"3512_CR131","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1523\/JNEUROSCI.4944-04.2005","volume":"25","author":"DE Naylor","year":"2005","unstructured":"Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25:7724\u201333.","journal-title":"J Neurosci"},{"key":"3512_CR132","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1523\/JNEUROSCI.4346-07.2008","volume":"28","author":"M Terunuma","year":"2008","unstructured":"Terunuma M, Xu J, Vithlani M, Sieghart W, Kittler J, Pangalos M, et al. Deficits in phosphorylation of GABA(A) receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus. J Neurosci. 2008;28:376\u201384.","journal-title":"J Neurosci"},{"key":"3512_CR133","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.3426-07.2008","volume":"28","author":"HP Goodkin","year":"2008","unstructured":"Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit-specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci. 2008;28:2527\u201338.","journal-title":"J Neurosci"},{"key":"3512_CR134","doi-asserted-by":"publisher","first-page":"9665","DOI":"10.1073\/pnas.93.18.9665","volume":"93","author":"A Rice","year":"1996","unstructured":"Rice A, Rafiq A, Shapiro SM, Jakoi ER, Coulter DA, DeLorenzo RJ. Long-lasting reduction of inhibitory function and gamma-aminobutyric acid type A receptor subunit mRNA expression in a model of temporal lobe epilepsy. Proc Natl Acad Sci USA. 1996;93:9665\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3512_CR135","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1152\/jn.01180.2007","volume":"99","author":"HJ Feng","year":"2008","unstructured":"Feng HJ, Mathews GC, Kao C, Macdonald RL. Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol. 2008;99:1285\u201393.","journal-title":"J Neurophysiol"},{"key":"3512_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.npp.1301195","volume":"32","author":"J Tornberg","year":"2007","unstructured":"Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS. KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007;32:911\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"3512_CR137","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/ejn.12241","volume":"38","author":"TZ Deeb","year":"2013","unstructured":"Deeb TZ, Nakamura Y, Frost GD, Davies PA, Moss SJ. Disrupted Cl(-) homeostasis contributes to reductions in the inhibitory efficacy of diazepam during hyperexcited states. Eur J Neurosci. 2013;38:2453\u201367.","journal-title":"Eur J Neurosci"},{"key":"3512_CR138","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1111\/epi.17097","volume":"63","author":"DL Cheung","year":"2022","unstructured":"Cheung DL, Cooke MJ, Goulton CS, Chaichim C, Cheung LF, Khoshaba A, et al. Global transgenic upregulation of KCC2 confers enhanced diazepam efficacy in treating sustained seizures. Epilepsia. 2022;63:e15\u2013e22.","journal-title":"Epilepsia"},{"key":"3512_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100957","volume":"4","author":"R Jarvis","year":"2023","unstructured":"Jarvis R, Josephine Ng SF, Nathanson AJ, Cardarelli RA, Abiraman K, Wade F, et al. Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice. Cell Rep Med. 2023;4:100957.","journal-title":"Cell Rep Med"},{"key":"3512_CR140","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.bjp.0701365","volume":"122","author":"KS Hand","year":"1997","unstructured":"Hand KS, Baird VH, Van Paesschen W, Koepp MJ, Revesz T, Thom M, et al. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Br J Pharmacol. 1997;122:358\u201364.","journal-title":"Br J Pharmacol"},{"key":"3512_CR141","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0140-6736(88)92468-3","volume":"2","author":"I Savic","year":"1988","unstructured":"Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet. 1988;2:863\u20136.","journal-title":"Lancet"},{"key":"3512_CR142","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/brain\/121.11.2067","volume":"121","author":"P Ryvlin","year":"1998","unstructured":"Ryvlin P, Bouvard S, Le Bars D, De Lamerie G, Gregoire MC, Kahane P, et al. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain. 1998;121:2067\u201381.","journal-title":"Brain"},{"key":"3512_CR143","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/brain\/awh470","volume":"128","author":"S Bouvard","year":"2005","unstructured":"Bouvard S, Costes N, Bonnefoi F, Lavenne F, Mauguiere F, Delforge J, Ryvlin P. Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. Brain. 2005;128:1330\u201343.","journal-title":"Brain"},{"key":"3512_CR144","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","volume":"55","author":"AL Malizia","year":"1998","unstructured":"Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715\u201320.","journal-title":"Arch Gen Psychiatry"},{"key":"3512_CR145","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0006-3223(99)00188-2","volume":"47","author":"JD Bremner","year":"2000","unstructured":"Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96\u2013106.","journal-title":"Biol Psychiatry"},{"key":"3512_CR146","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/clpt.1988.32","volume":"43","author":"PD Kroboth","year":"1988","unstructured":"Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects. Clin Pharmacol Ther. 1988;43:270\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"3512_CR147","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.1365-2125.2003.01964.x","volume":"57","author":"H Ihmsen","year":"2004","unstructured":"Ihmsen H, Albrecht S, Hering W, Schuttler J, Schwilden H. Modelling acute tolerance to the EEG effect of two benzodiazepines. Br J Clin Pharmacol. 2004;57:153\u201361.","journal-title":"Br J Clin Pharmacol"},{"key":"3512_CR148","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0014-2999(99)00013-8","volume":"368","author":"M Fujita","year":"1999","unstructured":"Fujita M, Woods SW, Verhoeff NP, Abi-Dargham A, Baldwin RM, Zoghbi SS, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol. 1999;368:161\u201372.","journal-title":"Eur J Pharmacol"},{"key":"3512_CR149","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.pscychresns.2015.06.016","volume":"233","author":"GG Brown","year":"2015","unstructured":"Brown GG, Ostrowitzki S, Stein MB, von Kienlin M, Liu TT, Simmons A, et al. Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder. Psychiatry Res. 2015;233:394\u2013401.","journal-title":"Psychiatry Res"},{"key":"3512_CR150","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41386-024-01884-5","volume":"49","author":"S Wein","year":"2024","unstructured":"Wein S, Riebel M, Seidel P, Brunner LM, Wagner V, Nothdurfter C, et al. Local and global effects of sedation in resting-state fMRI: A randomized, placebo-controlled comparison between etifoxine and alprazolam. Neuropsychopharmacology. 2024;49:1738\u201348.","journal-title":"Neuropsychopharmacology"},{"key":"3512_CR151","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s42003-022-03268-1","volume":"5","author":"PB Lukow","year":"2022","unstructured":"Lukow PB, Martins D, Veronese M, Vernon AC, McGuire P, Turkheimer FE, Modinos G. Cellular and molecular signatures of in vivo imaging measures of GABAergic neurotransmission in the human brain. Commun Biol. 2022;5:372.","journal-title":"Commun Biol"},{"key":"3512_CR152","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2018.08.010","volume":"691","author":"JD Andersson","year":"2019","unstructured":"Andersson JD, Matuskey D, Finnema SJ. Positron emission tomography imaging of the gamma-aminobutyric acid system. Neurosci Lett. 2019;691:35\u201343.","journal-title":"Neurosci Lett"},{"key":"3512_CR153","doi-asserted-by":"publisher","first-page":"e1750232024","DOI":"10.1523\/JNEUROSCI.1750-23.2024","volume":"44","author":"A Johansen","year":"2024","unstructured":"Johansen A, Beliveau V, Colliander E, Raval NR, Dam VH, Gillings N, et al. An in vivo high-resolution human brain atlas of synaptic density. J Neurosci. 2024;44:e1750232024.","journal-title":"J Neurosci"},{"key":"3512_CR154","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jpsychires.2024.02.039","volume":"172","author":"J Badinier","year":"2024","unstructured":"Badinier J, Lopes R, Mastellari T, Fovet T, Williams SCR, Pruvo JP, Amad A. Clinical and neuroimaging predictors of benzodiazepine response in catatonia: A machine learning approach. J Psychiatr Res. 2024;172:300\u20136.","journal-title":"J Psychiatr Res"},{"key":"3512_CR155","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature08758","volume":"463","author":"KR Tan","year":"2010","unstructured":"Tan KR, Brown M, Labou\u00e8be G, Yvon C, Creton C, Fritschy J-M, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769\u201374.","journal-title":"Nature"},{"key":"3512_CR156","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0405621102","volume":"102","author":"JK Rowlett","year":"2005","unstructured":"Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci. 2005;102:915\u201320.","journal-title":"Proc Natl Acad Sci"},{"key":"3512_CR157","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jamapsychiatry.2022.1150","volume":"79","author":"L Peng","year":"2022","unstructured":"Peng L, Meeks TW, Blazes CK. Complex persistent benzodiazepine dependence-when benzodiazepine deprescribing goes awry. JAMA Psychiatry. 2022;79:639\u201340.","journal-title":"JAMA Psychiatry"},{"key":"3512_CR158","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/hex.13392","volume":"25","author":"T Lynch","year":"2022","unstructured":"Lynch T, Ryan C, Cadogan CA. \u2018I just thought that it was such an impossible thing\u2019: A qualitative study of barriers and facilitators to discontinuing long-term use of benzodiazepine receptor agonists using the Theoretical Domains Framework. Health Expect. 2022;25:355\u201365.","journal-title":"Health Expect"},{"key":"3512_CR159","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2016.01.010","volume":"89","author":"KL Villa","year":"2016","unstructured":"Villa KL, Berry KP, Subramanian J, Cha JW, Oh WC, Kwon HB, et al. Inhibitory synapses are repeatedly assembled and removed at persistent sites in vivo. Neuron. 2016;89:756\u201369.","journal-title":"Neuron"},{"key":"3512_CR160","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1124\/pr.117.014449","volume":"70","author":"W Sieghart","year":"2018","unstructured":"Sieghart W, Savic MM. International Union of Basic and Clinical Pharmacology. CVI: GABA(A) receptor subtype- and function-selective ligands: Key issues in translation to humans. Pharmacol Rev. 2018;70:836\u201378.","journal-title":"Pharmacol Rev"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03512-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:02:25Z","timestamp":1781510545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03512-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3512"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03512-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}